Response Genetics to Present at the 25th Annual ROTH Conference

Response Genetics to Present at the 25th Annual ROTH Conference

LOS ANGELES, March 12, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX), a company focused on the development and sale of molecular
diagnostic tests for cancer, announced today that Thomas A. Bologna, Chairman
and CEO, will present at the 25^th Annual ROTH Conference in Laguna Niguel,

Mr. Bologna's presentation is scheduled to begin at 4:00 p.m. PDT on March 19,
2013. Interested investors can access a live webcast of the presentation by
going to the Investor Relations tab on the Response Genetics website:

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer. The Company's technologies enable extraction and analysis
of genetic information derived from tumor cells stored as formalin-fixed and
paraffin-embedded specimens. The Company's principal customers include
oncologists and pathologists. In addition to diagnostic testing services, the
Company generates revenue from the sale of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry. The Company's headquarters is located in Los Angeles,
California. For more information, please visit

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties.
Such statements may include, without limitation, statements with respect to
the Company's plans, objectives, projections, expectations and intentions,
such as the ability of the Company, to provide clinical testing services to
the medical community, to continue to expand its sales force, to continue to
build its digital pathology initiative, to attract and retain qualified
management, to strengthen marketing capabilities, to expand the suite of
ResponseDX^® products, to continue to provide clinical trial support to
pharmaceutical clients, to enter into new collaborations with pharmaceutical
clients, to enter into areas of companion diagnostics, to continue to execute
on its business strategy and operations, to continue to analyze cancer samples
and the potential for using the results of this research to develop diagnostic
tests for cancer, the usefulness of genetic information to tailor treatment to
patients, and other statements identified by words such as "project," "may,"
"could," "would," "should," "believe," "expect," "anticipate," "estimate,"
"intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities Exchange
Commission. Actual results, including, without limitation, actual sales
results, if any, or the application of funds, may differ from those set forth
in the forward-looking statements. These forward-looking statements involve
certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company's control). The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer
Press spacebar to pause and continue. Press esc to stop.